Hematopoiesis constitutes an evolutionary process in which cell-fate decisions are driven through epigenetic modifications resulting in changes in gene expression ultimately determining whether a cell undergoes differentiation, proliferation, cell-cycle arrest, or apoptosis. Recent developments in sequencing techniques and bio-informatic tools have increased our understanding of epigenetics. However, epigenetic regulation of hematopoiesis remains incompletely understood. Furthermore, the genetic and epigenetic dysregulation observed in aberrant hematopoiesis adds another layer of complexity.
The aims of this Research Topic are (1) to review the epigenetic landscape and transcriptional control of (aberrant) hematopoiesis and (2) to cover timely and novel discoveries based on either fundamental or translational research on epigenetic modifiers, transcription factors, RNA splicing factors, and related proteins. This includes but is not limited to studies further elucidating the effects of mutations in epigenetic regulators and transcription factors on benign and malignant hematopoiesis.
Furthermore, we encourage submissions of case reports and articles with clinically meaningful results in which an original hypothesis is rejected but that are still impactful to the scientific/medical community. Additionally, unpublished data may be added to support review and opinion pieces.
Areas to be covered in this section of Genome Organization, Structure, and Dynamics may include but are not limited to:
• Transcriptional programs in health and disease during hematopoiesis
• RNA splicing, RNA modification, and nonsense-mediated RNA-decay
• Epigenetic regulation and reprogramming in regular hematopoiesis and disease
Prof. Zeiser declares speaker fees from Novartis, Incyte, Sanofi, MNK.
Hematopoiesis constitutes an evolutionary process in which cell-fate decisions are driven through epigenetic modifications resulting in changes in gene expression ultimately determining whether a cell undergoes differentiation, proliferation, cell-cycle arrest, or apoptosis. Recent developments in sequencing techniques and bio-informatic tools have increased our understanding of epigenetics. However, epigenetic regulation of hematopoiesis remains incompletely understood. Furthermore, the genetic and epigenetic dysregulation observed in aberrant hematopoiesis adds another layer of complexity.
The aims of this Research Topic are (1) to review the epigenetic landscape and transcriptional control of (aberrant) hematopoiesis and (2) to cover timely and novel discoveries based on either fundamental or translational research on epigenetic modifiers, transcription factors, RNA splicing factors, and related proteins. This includes but is not limited to studies further elucidating the effects of mutations in epigenetic regulators and transcription factors on benign and malignant hematopoiesis.
Furthermore, we encourage submissions of case reports and articles with clinically meaningful results in which an original hypothesis is rejected but that are still impactful to the scientific/medical community. Additionally, unpublished data may be added to support review and opinion pieces.
Areas to be covered in this section of Genome Organization, Structure, and Dynamics may include but are not limited to:
• Transcriptional programs in health and disease during hematopoiesis
• RNA splicing, RNA modification, and nonsense-mediated RNA-decay
• Epigenetic regulation and reprogramming in regular hematopoiesis and disease
Prof. Zeiser declares speaker fees from Novartis, Incyte, Sanofi, MNK.
